Search our Innovation Portfolio

Oncimmune aims to develop EarlyCDT-Lung+ as a test to help with the earlier identification of lung cancer in patients with indeterminate pulmonary nodules (IPNs). The resulting new blood test will enable the stratification of higher risk IPNs and ensure those patients at higher risk of malignancy receive further interventions, such as PET-CT, or endobronchial ultrasound supported biopsy to diagnose the cancer as early as possible.

The project will combine Oncimmune's capabilities in project management and data analysis with health economics and patient involvement at University of Leeds and biochemistry from Leeds Teaching Hospitals NHS Trust.

Skin Analytics has already developed an AI melanoma screening tool for use assessing pigmented lesions in primary care and earlier. Two additional technologies could, when coupled with our existing melanoma service, significantly improve the quality of onward referrals into secondary care and enable cost effective population based screening.

These are a non-melanoma skin cancer screening tool, and a change analysis tool. In phase 1 we will develop these tools and aim to show performance levels that indicate that a combined service product can be developed and deployed to significantly improve the skin cancer pathway (phase 2).

Skin Analytics’ Class II UKCA-Certified Artificial Intelligence Medical Device can support the assessment of skin lesions where there is a suspicion of skin cancer. This technology will be deployed in Community Diagnostic Hubs in pathways co-created with three NHS partners to support faster skin cancer detection and pathway conversion rates.